153 related articles for article (PubMed ID: 22065071)
1. Midterm clinico-radiologic findings of an open label observation study of add-on tacrolimus with biologics or non-biologic DMARDs.
Takakubo Y; Tamaki Y; Hirayama T; Iwazaki K; Yang S; Sasaki A; Nakano H; Konttinen YT; Takagi M
Rheumatol Int; 2012 Nov; 32(11):3487-94. PubMed ID: 22065071
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus.
Ishida K; Shiraki K; Yoshiyasu T
Drugs R D; 2015 Dec; 15(4):307-17. PubMed ID: 26386566
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate.
Kitahama M; Nakajima A; Inoue E; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2013 Jul; 23(4):788-93. PubMed ID: 22975732
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis.
Nakajima A; Inoue E; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2016 Nov; 26(6):836-843. PubMed ID: 26934454
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan.
Takeuchi T; Ishida K; Shiraki K; Yoshiyasu T
Mod Rheumatol; 2018 Jan; 28(1):48-57. PubMed ID: 28649878
[TBL] [Abstract][Full Text] [Related]
6. Single-center, retrospective analysis of efficacy and safety of tacrolimus as a second-line DMARD in combination therapy and the risk factors contributing to adverse events in 115 patients with rheumatoid arthritis.
Ogasawara M; Tamura N; Kageyama M; Onuma S; Kusaoi M; Toyama S; Sekiya F; Matsudaira R; Nawata M; Tada K; Matsushita M; Kempe K; Amano H; Morimoto S; Yamaji K; Takasaki Y
Clin Rheumatol; 2012 Feb; 31(2):251-7. PubMed ID: 21773713
[TBL] [Abstract][Full Text] [Related]
7. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables.
Aramaki T; Kawakami A; Iwamoto N; Fujikawa K; Kawashiri SY; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Nakashima M; Mizokami A; Furuyama M; Matsuoka N; Ueki Y; Ida H; Origuchi T; Aoyagi K; Eguchi K
Mod Rheumatol; 2009; 19(6):652-6. PubMed ID: 19787419
[TBL] [Abstract][Full Text] [Related]
8. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
Takahashi N; Fujibayashi T; Kida D; Hirano Y; Kato T; Kato D; Saito K; Kaneko A; Yabe Y; Takagi H; Oguchi T; Miyake H; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Hanabayashi M; Hirabara S; Asai S; Takemoto T; Terabe K; Asai N; Yoshioka Y; Ishiguro N; Kojima T
Rheumatol Int; 2015 Oct; 35(10):1707-16. PubMed ID: 25991396
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of tacrolimus on progression of joint damage in patients with rheumatoid arthritis.
Motomura H; Matsushita I; Seki E; Mine H; Kimura T
Int J Rheum Dis; 2014 Sep; 17(7):749-54. PubMed ID: 24251619
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.
Naniwa T; Iwagaitsu S; Kajiura M
Int J Rheum Dis; 2018 Mar; 21(3):673-687. PubMed ID: 29314738
[TBL] [Abstract][Full Text] [Related]
11. Drug survival and the associated predictors in South Korean patients with rheumatoid arthritis receiving tacrolimus.
Park EY; Lee SG; Park EK; Koo DW; Park JH; Kim GT; Tag HS; Kim HO; Suh YS
Korean J Intern Med; 2018 Jan; 33(1):193-202. PubMed ID: 27048254
[TBL] [Abstract][Full Text] [Related]
12. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
13. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness and safety of additional administration of tacrolimus in rheumatoid arthritis patients with an inadequate response to abatacept: A retrospective cohort study.
Suzuki M; Takahashi N; Kida D; Hirano Y; Kato T; Yabe Y; Oguchi T; Fujibayashi T; Hayashi M; Asai S; Ishiguro N; Kojima T
Int J Rheum Dis; 2019 Dec; 22(12):2199-2205. PubMed ID: 31647174
[TBL] [Abstract][Full Text] [Related]
15. Depression is improved when low-dose tacrolimus is given to rheumatoid arthritis patients showing an inadequate response to biologic agents.
Miwa Y; Hosaka M; Ohtsuka K; Sato M; Takahashi R; Wakabayashi K; Odai T; Yajima N; Kasama T
Mod Rheumatol; 2013 Sep; 23(5):920-4. PubMed ID: 22990336
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tacrolimus in infliximab-refractory progressive rheumatoid arthritis.
Yokota K; Akiyama Y; Asanuma Y; Miyoshi F; Sato K; Mimura T
Rheumatol Int; 2009 Feb; 29(4):459-61. PubMed ID: 18802706
[TBL] [Abstract][Full Text] [Related]
17. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate.
Shin K; Baek HJ; Kang YM; Cha HS; Kang SW; Park SH; Jun JB; Lee YJ; Choi IA; Song YW
Int J Rheum Dis; 2019 Jun; 22(6):1115-1122. PubMed ID: 30861334
[TBL] [Abstract][Full Text] [Related]
19. Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients.
Naito T; Ohshiro J; Sato H; Torikai E; Suzuki M; Ogawa N; Kawakami J
Clin Biochem; 2019 Jul; 69():8-14. PubMed ID: 31077643
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
